JMT101

JMT101 is a monoclonal antibody developed by Shanghai JMT-Bio. Its target is EGFR (the sponsor names EGFR). The sponsor states: JMT101 is a recombinant humanised anti-EGFR monoclonal antibody, given intravenously (6 mg/kg every two weeks) in combination with osimertinib versus osimertinib alone in EGFR-mutant non-small cell lung cancer. ClinicalTrials.gov describes the intervention as: JMT101 is a recombinant humanized anti-EGFR monoclonal antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06735391 (A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations), in non-small-cell lung cancer. The largest, NCT06735391, plans to enrol 516 participants with primary completion expected 2026-09-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.